Elecsys® β-Amyloid(1-42) CSF

ElectroChemiLuminescence Immunoassay (ECLIA) for the in vitro quantitative determination of β-Amyloid(1-42) in human Cerebrospinal Fluid (CSF)

β-Amyloid (1-42) peptide deposition in the brain is one of the two hallmarks of Alzheimer’s Disease (AD), besides neurofibrillary tangles. Pathological changes in the β-Amyloid metabolism are the earliest alterations during AD development. These changes are reflected by the decrease in the CSF concentrations of β-Amyloid (1-42) as well as by the increase in the brain uptake of the specific tracers on the β-Amyloid PET.¹

Elecsys^® β-Amyloid(1-42) CSF II (AB42 2) is an in vitro diagnostic immunoassay intended for the quantitative determination of the β-Amyloid(1-42) protein concentration in human cerebrospinal fluid (CSF).²

Elecsys^® AB42 2 assay is part of the Elecsys^® AD portfolio, along with Elecsys^® Phospho-Tau (181P) CSF (pTau) and Elecsys® Total-Tau CSF (tTau) immunoassays.²

Elecsys^® AD CSF assays can detect amyloid positivity, enhancing diagnostic accuracy and physician confidence.^3,4

Elecsys^® AD CSF assays enable timely intervention by identifying patients with MCI at risk of progression to AD.^2,4

Contact

References

Lewczuk, P. et al. 2015). Advances in Medical Sciences 60, 76-82
Elecsys® Method Sheet: ms_08821941500V1.0, ms_08821909500V1.0, ms_08846715500V1.0, ms_08846693500V1.0, ms_08846634500V1.0, ms_08846685500V1.0
Rabinovici, G.D. et al. (2019). Association of Amyloid Positron Emission Tomography With Subsequent Change in Clinical Management Among Medicare Beneficiaries With Mild Cognitive Impairment or Dementia. JAMA 321(13), 1286-1294.
Hansson, O. et al. (2018). CSF biomarkers of Alzheimer’s disease concord with amyloid-β PET and predict clinical progression: A study of fully automated immunoassays in BioFINDER and ADNI cohorts. Alzheimers Dement 14(11), 1470-1481